Nemolizumab (Nemluvio, Galderma) maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions, and quality of life up to three years in patients with moderate-to-severe prurigo nodularis (PN), according to an interim analysis of the OLYMPIA long-term extension (LTE).
The results will be presented at 2026 Winter Clinical Miami.
The OLYMPIA LTE study was designed to assess the safety and efficacy of nemolizumab in patients with PN for up to four years and included 508 patients from the Phase 2 trial and the OLYMPIA 1 and 2 Phase 3 trials. At week 148, in evaluable patients, the interim analysis showed that nemolizumab maintained long-term disease control with a consistent safety profile:
More than 70% of patients achieved Clear or Almost Clear skin lesions based on Investigator’s Global Assessment score, and over 85% achieved more than 75% of healed lesions based on prurigo activity score.
-
- More than 85% of patients achieved a clinically meaningful itch improvement, and about three-quarters attained an itch-free or nearly itch-free state.
- About 90% of patients achieved a clinically meaningful improvement in quality of life, and >50% achieved a Dermatology Life Quality Index score of zero or one, meaning no effect of the disease on quality of life.
- The long-term safety profile of nemolizumab remained consistent with previous findings and aligned with previously established safety data for PN.
“Prurigo nodularis is not only intensely itchy, painful, and uncomfortable, it can also take a profound toll on sleep, emotional well-being, and daily functioning,” says Shawn Kwatra, MD, the Joseph W. Burnett Endowed Professor and Chair of Dermatology at the University of Maryland School of Medicine and Chief of Service Dermatology at the University of Maryland Medical Center in Baltimore, MD, in a news release. “That’s why achieving sustained, long-term disease control is critical for patients. These data show that Nemluvio can make a meaningful difference to people’s lives by improving itch, skin lesions, and quality of life up to three years, with a well-tolerated safety profile.”
Nemolizumab is the first approved monoclonal antibody that specifically targets interleukin (IL)-31 receptor alpha. It was approved by the US Food and Drug Administration (FDA) for the treatment of adults with PN, and patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. To date, nemolizumab is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the EU, Australia, Singapore, Switzerland, and the United Kingdom. Additional regulatory submissions and reviews are ongoing.